experienced attacks of similar pain occurring once or twice a week with no systemic upset or alteration of bowel habit. His temperature was 38°C, and there was tenderness and guarding in the right iliac fossa. Rectal examination showed normal stools and right-sided tenderness. White cell count was $15 \times 10^9/l$ ($15\,000/mm^3$) with 70% neutrophils, haemoglobin 14.6 g/dl. At laparotomy the same day the terminal ileum was inflamed and oedematous, as was the mesentery, which contained numerous enlarged lymph nodes. The appearances and the history suggested an acute exacerbation of Crohn's disease and ileocaecal resection was performed.

Postoperatively he developed a chest infection, which was treated with ampicillin; there were no other complications. Now, 18 months later, he is asymptomatic and barium follow-through examination shows a normal small intestine.

The terminal ileum was thickened and inflamed and the mucosa showed multiple small ulcers 5-10 mm in diameter, particularly in the region of the ileocaecal valve. The mesenteric nodes were enlarged; the appendix and large bowel were normal. These naked eye appearances were suggestive of Crohn's disease. Sections of the ileum showed inflammation mainly in the mucosa and submucosa (see figure). There were abscess-like aggregates of inflammatory cells near the mucosal surface, and some of these had ruptured producing ulceration. Occasional granulomata with giant cells were seen. The appendix was normal and the mesenteric nodes showed reactive hyperplasia only.

Section from ulcerated area of terminal ileum showing mucosal ulceration with intense submucosal inflammation and microabscess formation (H and E $\times 6$).

Yersinia ileitis was suspected, but there was difficulty in obtaining blood for serological testing until five weeks after operation. At this time antibodies to *Yersinia pseudotuberculosis* type III were demonstrated at a titre of 1/320. For further confirmation a skin test with this antigen was performed 10 weeks postoperatively. After 48 hours a 3-cm zone of erythema was considered positive.

Discussion

Since Knapp and Masshoff¹ first isolated *Y. pseudotuberculosis* from mesenteric lymph nodes this infection has been increasingly recognised.²⁻⁴ At laparotomy the appendix is often normal, the mesenteric nodes are enlarged and may be purulent, and sometimes the terminal ileum is inflamed. It has been recommended^{3,4} that the appendix and enlarged nodes should be excised and examined histologically and bacteriologically. Serological tests for yersinia should be carried out during the acute illness and one month later. If this is done the diagnosis will be established more frequently. In our case yersinia ileitis was not suspected clinically mainly because of the chronic history. Nevertheless, the results of serological tests performed five weeks after operation were considered diagnostic, since Mair² has shown that the antibody titre declines rapidly from a peak two weeks postoperatively to virtually nil after five months.

It is now recognised that acute terminal ileitis rarely progresses to chronic Crohn's disease.⁵ Crohn's disease may present acutely but there is usually some previous history or other evidence of chronicity at laparotomy or on barium meal examination. This case history emphasises the importance of considering a diagnosis of yersinia ileitis even when symptoms have been present for some months, to avoid a mistaken diagnosis of Crohn's disease with its more serious prognosis.

We thank Dr C R Tribe and Dr B C Morson for help and advice; Dr N S Mair of the Public Health Laboratory, Leicester, for the serological tests and for kindly supplying the skin test antigen, and Mr M Wilson for permission to publish the case.

¹ Knapp, W, and Masshoff, W, *Deutsche medizinische Wochenschrift*, 1954, **79**, 1266.

² Mair, N S, *et al*, *Journal of Clinical Pathology*, 1960, **13**, 433.

³ Weber, J, Finlayson, N B, and Mark, J, *New England Journal of Medicine*, 1970, **283**, 172.

⁴ Gurry, J F, *British Medical Journal*, 1974, **2**, 264.

⁵ Gump, F E, Lepore, M, and Barker, H G, *Annals of Surgery*, 1967, **166**, 942.

Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB

A SAVAGE, MB, BS, senior registrar in pathology

D DUNLOP, FRCS, registrar in surgery

Nephrotic syndrome in vesicoureteric reflux

The association of vesicoureteric reflux and chronic pyelonephritis is well recognised, and in such cases minimal proteinuria may occur. Nevertheless, when heavy proteinuria (>3 g/24 hours) occurs in association with reflux a glomerular lesion should be suspected. We report a case of such an association and speculate on a possible mechanism.

Case report

A 12-year-old boy first presented in 1967 with a two-month history of recurrent episodes of painful micturition associated with fever and rigors. Investigations included a micturating cystourethrogram, which showed gross, bilateral reflux. He was prescribed antibiotics for recurrent urinary tract infections and was discharged from follow-up in 1969. At that time the blood urea nitrogen was normal.

In 1971 he re-presented with a six-month history of periorbital oedema. The results of relevant investigations at that time were: 24-hour urinary protein excretion 6 g; protein-excretion selectivity index 0.18 (poor selectivity); total serum protein 35 g/l; serum albumin 15 g/l; creatinine clearance 18 ml/min. On renal biopsy, basement membrane thickening, consistent with a diagnosis of membranous glomerulonephritis, was found (see figure). By October 1974 creatinine clearance had decreased to 5 ml/min, and in January 1975 he was admitted to hospital with clinical uraemia and pulmonary oedema precipitated by administration of tetracycline for an upper respiratory tract infection.

He was initially managed with peritoneal dialysis, and, as there was no improvement in renal function, regular haemodialysis therapy was started. Bilateral nephrectomy was performed in July 1975. Tissue histology confirmed the diagnosis of membranous glomerulonephritis and immuno-

Renal biopsy obtained in 1971, showing thickening of glomerular basement membrane (H and E stain).

fluorescent staining for IgG was positive. A cadaver renal transplant was performed in August 1975, but this subsequently failed and the patient has now returned to regular haemodialysis therapy.

Discussion

Massive proteinuria with nephrotic syndrome has been reported in vesicoureteric reflux and in chronic pyelonephritis.^{1,2} Possibly the association is purely coincidental, but this would seem unlikely. Membranous glomerulonephritis has been produced experimentally by the injection of homologous renal tubular epithelial antigen,³ and tubular epithelial antigen has been demonstrated deposited on the glomeruli in membranous glomerulonephritis.⁴ Possibly tubular epithelial antigen is released into the circulation in reflux as a consequence of renal tubular injury, or, contact with immune competent cells is via the inflammatory cell infiltrate. Whatever the mechanism, failure to recognise the antigen as "self" might result in antibody formation. With persistent antigenic stimulation, immune complexes would form, thus providing the mechanism of glomerular injury. Tubular epithelial antigen was not demonstrated in the glomeruli of this patient but this does not necessarily invalidate the postulate.⁵

We suggest that measurement of proteinuria may be indicated in vesicourethral reflux. When massive proteinuria is found, a renal biopsy should be performed as the finding of glomerulopathy may well alter the natural history of the reflux.

We are grateful to Dr D K Peters for his help with antigen elution studies.

¹ Pillay, V K G, *et al*, *Lancet*, 1969, **2**, 1272.

² Dayan, S, and Smith, E C, *Journal of Urology*, 1976, **110**, 108.

³ Edgington, T S, *et al*, *Journal of Experimental Medicine*, 1968, **127**, 555.

⁴ Naruse, T, *et al*, *Journal of Immunology*, 1973, **110**, 1163.

⁵ Braunstein, G D, *et al*, *American Journal of Medicine*, 1970, **48**, 643.

Area Renal Unit, Leicester General Hospital

H F WOODS, MRCP, registrar

J WALLS, MRCP, consultant nephrologist

Responses to vincristine in refractory idiopathic thrombocytopenic purpura

Recent reports indicate that the periwinkle alkaloid vincristine, by producing thrombocytosis, may be useful in the treatment of idiopathic thrombocytopenic purpura (ITP).^{1,2} Adult patients with ITP who are resistant to steroid treatment present a problem, especially when they require surgery or develop bleeding complications. Splenectomy produces a response in only about half of adults, and the other commonly used immunosuppressants, cyclophosphamide and azathioprine, are slow in producing an effect.

We have assessed the response to vincristine in nine patients with chronic ITP who were wholly or partly refractory to steroids. The history of thrombocytopenia ranged between one and 18 years. Vincristine was given by weekly intravenous injections of 2 mg until

either a response was obtained or the patient experienced unacceptable side effects. The details of the patients are listed in the table. The platelet counts are shown before vincristine and one to two weeks and one to two months after the first injection.

Patients treated

Patient 1 responded very rapidly, the platelet count rising from $34 \times 10^9/l$ to $360 \times 10^9/l$ even after her steroids were tailed off; previously she had required a maintenance dose of 40 mg of prednisolone a day. Patients 2, 3, 4, and 5 had a good response, with the platelet count rising to over $100 \times 10^9/l$, but they relapsed within three weeks of the first injection. Of these four patients, only patient 3 had ever responded to steroids and she required 60 mg of prednisolone a day to obtain a satisfactory platelet count. Patients 6, 7, 8, and 9 had a poor temporary response. The patients who responded showed an increase in platelet count a week after the first injection but this was sustained with further weekly doses in only three patients.

None of the patients developed any evidence of bone-marrow suppression on this dose and the limiting factor to further administration of vincristine was the recognised side effect of peripheral neuropathy, the symptoms of which appeared to be unusually prominent. It was not possible to predict the response to vincristine from the previous failure to respond to splenectomy.

Discussion

Treatment with vincristine may produce a significant rise in the platelet count in refractory ITP. The mechanism by which it is produced is incompletely understood. Despite the fact that many cases of ITP have an autoimmune basis and that vincristine is known to produce immunosuppression in animals,³ it is not established that production of thrombocytosis is mediated through this action. In rats sublethal doses of vincristine have produced initial megakaryocyte suppression followed by reactive megakaryocytopoiesis and thrombocytosis. Low doses produced thrombocytosis only, but the authors postulated that the same rebound mechanism obtained.⁴

In our six patients with an initial moderate response the rise in platelet count was not maintained by continuing weekly vincristine at normal doses (0.025 mg/kg) and so little further benefit would result from long-term low-dose maintenance therapy. As suggested by Ahn *et al*² vincristine may tide the patient over until an immunosuppressive such as azathioprine, with fewer side effects but delayed action, produces a response.

In view of the temporary effect and the high incidence of side effects, routine use of vincristine in uncomplicated ITP is not indicated as primary treatment. Nevertheless, in refractory cases it may produce sufficient response to enable surgical techniques to be undertaken or be used as an interim measure in the management of bleeding complications.

¹ Robertson, J H, and McCarthy, G M, *Lancet*, 1969, **2**, 353.

² Ahn, Y S, *et al*, *New England Journal of Medicine*, 1974, **291**, 376.

³ Aisenberg, A C, and Wilkes, B, *Journal of Clinical Investigation*, 1964, **43**, 2394.

⁴ Choi, S, Simone, J V, and Edwards, C C, *Platelets*, ed M G Baldini and S Ebbe. New York, Grune and Stratton, 1974.

Department of Haematology, The General Infirmary, Leeds

I E BURTON, MRCP, MRCPATH, senior registrar in haematology

B E ROBERTS, MD, MRCPATH, consultant haematologist

J A CHILD, MD, MRCP, consultant clinical haematologist

Department of Haematology, Kingston General Hospital, Hull

D A MONTGOMERY, MRCPATH, consultant haematologist

C G L RAPER, MRCP, MRCPATH, consultant haematologist

Summary of clinical details and response to vincristine

Case No	Age	Sex	Splenectomy	Antinuclear factor	Platelet count ($\times 10^9/l$)			Total dose vincristine (mg)
					Pretreatment	Max response (1-2 weeks)	Post-treatment (1 month)	
1	65	F	No	Negative	34	360	115	4
2	45	F	1960	Positive 1/10	3	120	8	8
3	66	F	No	Negative	20	120	10	6
4	40	F	No	Negative	64	144	52	6
5	80	M	No	Negative	54	136	10	7
6	57	F	No	Negative	18	71	20	7
7	66	F	No	Positive 1/40	28	50	40	3.5
8	43	M	1956	—	18	28	8	8
9	53	F	1975	Weak positive	30	60	20	2